Teva Pharmaceutical Industries (NYSE: TEVA) reported earnings on May 2. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Teva Pharmaceutical Industries met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped. Non-GAAP earnings per share dropped significantly. GAAP earnings per share dropped significantly.

Gross margins increased, operating margins shrank, net margins dropped.

Revenue details
 Teva Pharmaceutical Industries booked revenue of $4.90 billion. The 21 analysts polled by S&P Capital IQ looked for revenue of $4.86 billion on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $1.12. The 23 earnings estimates compiled by S&P Capital IQ predicted $1.11 per share. Non-GAAP EPS of $1.12 for Q1 were 24% lower than the prior-year quarter's $1.47 per share. GAAP EPS of $0.74 for Q1 were 24% lower than the prior-year quarter's $0.97 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 52.8%, 60 basis points better than the prior-year quarter. Operating margin was 17.8%, 440 basis points worse than the prior-year quarter. Net margin was 12.9%, 390 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $4.97 billion. On the bottom line, the average EPS estimate is $1.21.

Next year's average estimate for revenue is $20.17 billion. The average EPS estimate is $5.04.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,438 members out of 2,509 rating the stock outperform, and 71 members rating it underperform. Among 526 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 519 give Teva Pharmaceutical Industries a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Teva Pharmaceutical Industries is outperform, with an average price target of $45.31.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Teva Pharmaceutical Industries. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.